Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101791786 | 10179178 | 6 | F | 20110923 | 20160902 | 20140519 | 20160913 | EXP | US-SA-2014SA062283 | AVENTIS | 68.00 | YR | E | F | Y | 61.23000 | KG | 20160913 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101791786 | 10179178 | 1 | PS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | U | UNKNOWN | 20839 | 75 | MG | TABLET | QD | |||||
| 101791786 | 10179178 | 2 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | STRENGTH: 25 MG | 0 | 1 | DF | TABLET | QD | ||||||
| 101791786 | 10179178 | 3 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | STRENGTH: 25 MG | 0 | TABLET | |||||||||
| 101791786 | 10179178 | 4 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | STRENGTH: 10 MG AT BEDTIME | 0 | 1 | DF | TABLET | QD | ||||||
| 101791786 | 10179178 | 5 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | STRENGTH: 10 MG AT BEDTIME | 0 | TABLET | |||||||||
| 101791786 | 10179178 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 0 | 325 | MG | QD | |||||||||
| 101791786 | 10179178 | 7 | C | ASPIRIN. | ASPIRIN | 1 | 0 | QD | |||||||||||
| 101791786 | 10179178 | 8 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | STRENGTH: 40 MG AT BEDTIME | 0 | 1 | DF | TABLET | QD | ||||||
| 101791786 | 10179178 | 9 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | STRENGTH: 40 MG AT BEDTIME | 0 | TABLET | |||||||||
| 101791786 | 10179178 | 10 | C | LOVASTATIN. | LOVASTATIN | 1 | Oral | 0 | 1 | DF | TABLET | QD | |||||||
| 101791786 | 10179178 | 11 | C | TRIAMCINOLONE | TRIAMCINOLONE | 1 | Topical | 1 APP TOPICAL BID | 0 | CREAM | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101791786 | 10179178 | 1 | Stent placement |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101791786 | 10179178 | OT |
| 101791786 | 10179178 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101791786 | 10179178 | Balance disorder | |
| 101791786 | 10179178 | Cerebral haemorrhage | |
| 101791786 | 10179178 | Metabolic disorder | |
| 101791786 | 10179178 | Mobility decreased | |
| 101791786 | 10179178 | Multiple injuries | |
| 101791786 | 10179178 | Muscular weakness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 101791786 | 10179178 | 1 | 20110606 | 20110923 | 0 |